[^1]
| PDYN Protein |
|---|
| Protein Name | Prodynorphin |
| Gene | [PDYN](/genes/pdyn) |
| UniProt ID | [P01213](https://www.uniprot.org/uniprot/P01213) |
| Molecular Weight | ~28 kDa (precursor) |
| Subcellular Localization | Secreted, Dense core vesicles |
| Protein Family | Opioid peptide family |
PDYN (Prodynorphin) is the precursor protein encoded by the PDYN gene that gives rise to the dynorphin family of opioid peptides through proteolytic processing. Produced primarily in the central nervous system, particularly in the hypothalamus, striatum, and hippocampus, prodynorphin is cleaved by peptidases to generate active peptides including dynorphin A, dynorphin B, and leu-enkephalin.
These peptides act as endogenous ligands for the κ-opioid receptor (KOR), with some fragments also binding to δ-opioid receptors. The dynorphin/KOR system plays crucial roles in pain modulation, reward processing, stress response, mood regulation, and neuroendocrine function.
¶ Gene and Protein Structure
The PDYN gene is located on chromosome 20p13 and encodes a precursor protein of 254 amino acids. The gene contains multiple opioid peptide sequences within its coding region.
PDYN has a characteristic prepropeptide structure:
- Signal peptide: Directs protein to secretory pathway
- Multiple peptide sequences: Contains sequences for dynorphin A, dynorphin B, α/β-neoendorphin, leu-enkephalin
- Proteolytic cleavage sites: Paired basic residues (Lys-Arg) for processing
- C-terminal extension: Processed into active fragments
¶ Peptide Processing and Release
PDYN undergoes extensive proteolytic processing:
- Prohormone convertases: PC1/3 and PC2 process the precursor
- Active peptides generated: Dynorphin A (17 aa), dynorphin B (13 aa), leu-enkephalin
- Vesicular packaging: Stored in dense core vesicles
- Activity-dependent release: Released in response to neuronal firing
The dynorphin peptides bind to:
- κ-opioid receptor (KOR): Primary receptor, high affinity
- δ-opioid receptor (DOR): Lower affinity for some fragments
- μ-opioid receptor (MOR): Minimal binding
- Pain modulation: Analgesic effects through KOR activation
- Reward processing: Involved in dopamine regulation
- Stress response: Dysphoric effects via KOR
- Neuroendocrine regulation: Controls hormone release
- Mood regulation: Linked to depression and anxiety
PDYN is highly relevant to PD pathogenesis:
- Striatal expression: High in medium spiny neurons of the striatum
- Levodopa-induced dyskinesias: PDYN expression increases with chronic levodopa treatment
- Dopaminergic denervation: PDYN upregulation occurs following dopaminergic neuron loss
- KOR antagonism: May reduce dyskinesia severity
In AD, PDYN alterations have been reported:
- Hippocampal dysfunction: Altered dynorphin processing in AD brains
- Cognitive impairment: KOR activation may impair memory
- Amyloid interactions: Aβ may affect peptidergic systems
- Schizophrenia: PDYN variants associated with the disorder
- Depression: KOR antagonists as potential antidepressants
- Drug addiction: Dynorphin in reward pathway dysregulation
The dynorphin/KOR system is a therapeutic target:
- KOR antagonists: JNJ-67953964 (selective antagonist) in clinical trials
- Dyskinesia treatment: KOR modulation may reduce LID
- Depression/anxiety: Novel KOR antagonists show promise
- CSF dynorphin: May reflect neuronal activity
- Genetic variants: PDYN polymorphisms modify disease risk